Eli Lilly & Co.’s stock climbed 4.6% in active midday trade, enough to make it the second-biggest percentage gainer within the S&P 500, after the drug maker and Boehringer Ingelheim announced positive test results for their diabetes treatment, Jardiance. Volume was 4 million shares, nearly double the full-day average of 2.3 million share, according to FactSet. Eli Lilly and Boehringer said Jardiance demonstrated cardiovascular (CV) risk reduction in people with type-2 diabetes at high risk for CV events. “This comes as a surprise as no diabetes drugs, including insulin, have demonstrated CV benefit previously in the time frame of this study (average treatment [about] three years),” Leerink Partners analyst Seamus Fernandez wrote in a note to clients. He said he believe this was “significantly positive” for Eli Lilly’s diabetes franchise.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News

